| Literature DB >> 26519884 |
Yunus Amade Assane1, Chiara Trevisan2, Clara Maria Schutte3, Emilia Virginia Noormahomed4, Maria Vang Johansen5, Pascal Magnussen6.
Abstract
Neurocysticercosis (NCC) is an important neurological disease in countries with high prevalence of Taenia solium infection and is emerging as a serious public health and economic problem. The aim of this study was to estimate the prevalence of NCC in Angónia district, Tete province, Mozambique based on: prevalence of human T. solium cysticercosis assessed by antigen Enzyme-linked Immunosorbent Assay (Ag-ELISA) seropositivity, history of epilepsy, and brain computed tomography (CT) scan results. A cross sectional study was conducted between September and November 2007 in Angónia district. Questionnaires and blood samples were collected from 1,723 study subjects. Brain CT-scans were carried out on 151 study subjects with confirmed history of epilepsy. A total of 77 (51.0% (95% CI, 42.7-59.2)) and 38 (25.2% (95% CI, 18.5-32.9)) subjects met the criteria for definitive and probable diagnosis of NCC, respectively. T. solium Ag-ELISA seropositivity was found in 15.5% (95% CI, 12.8-16.2) of the study subjects. The estimated life time prevalence of epilepsy was 8.8% (95% CI, 7.5-10.2). Highly suggestive lesions of NCC were found on CT-scanning in 77 (71.9%, (95% CI, 62.4-80.2)) of the seropositive and 8 (18.1%, (95% CI, 8.2-32.7)) of the seronegative study subjects, respectively. The present findings revealed a high prevalence of NCC among people with epilepsy in Angónia district. Determination of effective strategies for prevention and control of T. solium cysticercosis are necessary to reduce the burden of NCC among the affected populations.Entities:
Keywords: Antigen Enzyme-linked Immunosorbent Assay; Computed tomography scan; Epilepsy; Mozambique; Neurocysticercosis; Taenia solium cysticercosis
Mesh:
Year: 2015 PMID: 26519884 PMCID: PMC6333921 DOI: 10.1016/j.actatropica.2015.10.018
Source DB: PubMed Journal: Acta Trop ISSN: 0001-706X Impact factor: 3.112
Fig. 1.Diagram showing the flow chart from questionnaire to CT-scanning.
Fig. 2.Three-set Venn diagram. Number of study subjects Ag-ELISA positive or negative and number of study subjects Ag-ELISA positive or negative with confirmed history of epilepsy.
Number and percentage (%) of study subjects Ag-ELISA seropositive and seronegative with a confirmed history of epilepsy and respective brain CT-scan findings.*
| Brain CT-scan findings | Ag-ELISA positive + epilepsy | Ag-ELISA negative + epilepsy | ||
|---|---|---|---|---|
| No. of study subjects | % | No. of study subjects | % | |
| Vesicular | 19 | 18.8 | 1 | 2.3 |
| Colloidal | 8 | 7.5 | 1 | 2.3 |
| Nodular-granular | 4 | 3.7 | 4 | 9.1 |
| Calcified | 35 | 32.7 | 2 | 4.5 |
| Fibrous arachnoiditis | 1 | 0.9 | 0 | 0.0 |
| Cysticercotic encephalitis | 3 | 2.8 | 0 | 0.0 |
| Vesicular + calcified | 7 | 6.5 | 0 | 0.0 |
| Normal CT-scan | 30 | 28.0 | 36 | 81.8 |
| Total | 107 | 100 | 44 | 100 |
CT: computed tomography scan; Ag-ELISA: antigen-Enzyme-Linked Immunosorbent Assay.